← Oncology Approval Tracker

FDA DECISION ·

Inqovi + venetoclax

oral decitabine and cedazuridine with venetoclax · Taiho Oncology

FDA approvalNew or expanded indicationAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Newly diagnosed AML in adults aged 75 or older or with comorbidities that preclude intensive induction chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The regimen offers an oral decitabine combination for a population with age or comorbidity constraints. Oral administration shifts some burden to adherence and outpatient monitoring.

What research teams should watch

Plan medication review, adherence support and timely lab follow-up. Keep the response findings in context as coming from a single-arm study.

PRIMARY RECORDS

Sources